Navigation Links
Pelikan Technologies Appoints Denny Ware to Board of Directors
Date:5/29/2008

Newest Board Member Brings Key Operational Experience and Broad Blood

Glucose Monitoring Industry Expertise

PALO ALTO, Calif., May 29 /PRNewswire/ -- Pelikan Technologies Inc., a leading developer of innovative hand-held diagnostic and monitoring devices, today announced the appointment of Dennert (Denny) Ware to its board of directors. Having most recently served as president and chief executive officer of Kinetic Concepts, Inc. (KCI), a global medical technology company, Mr. Ware brings vast operational and relevant industry experience to Pelikan's board. Under his leadership, revenue at KCI grew organically from approximately $300 million to $1.4 billion, making it one of the medical technology industry's fastest growing companies.

"We are very excited to have Denny join Pelikan's board," stated Pelikans president and chief executive officer, Dirk Boecker, M.D., Ph.D. "Not only does he have valuable first-hand experience in the blood glucose monitoring industry, he also has been responsible for generating tremendous revenue growth in the medical technology arena. This expertise will be particularly important for Pelikan as we ramp up our commercialization efforts for the Pelikan Sun(TM) electronic lancing device, as well as continue our development work on our next-generation, fully-integrated blood glucose system."

Prior to his work at KCI, Mr. Ware served as president and chief executive officer at Boehringer Mannheim Corporation, a market leader in the development and commercialization of innovative medical diagnostic equipment, particularly in the field of glucose monitoring and management for diabetics. Following Boehringer Mannheim's acquisition by F. Hoffman la Roche, he served as chief executive officer of Roche Diagnostics Corporation until joining KCI. Mr. Ware currently sits on the boards of Given Technologies, Inc., PharmacoPhotonics, Inc. and BioNumerik Pharmaceuticals, Inc.

"I am proud to join the board at Pelikan Technologies, a truly revolutionary company that is taking impressive strides to improve the manner in which people with diabetes live with and manage their disease," said Mr. Ware. "I believe my experience in the medical technology and glucose monitoring industries can assist Pelikan in its mission of developing and commercializing innovative devices that dramatically improve the lives of people with diabetes."

"We believe that Denny's formidable background and range of outstanding achievements in our industry position him as an excellent addition to Pelikan's board of directors," stated Gerald Moeller, Ph.D., executive chairman of the board for Pelikan Technologies. "We look forward to working with Denny and are excited for the important contributions that he will make to the company's success."

About Pelikan Technologies

Pelikan Technologies Inc. combines novel and proprietary blood sampling and measurement techniques with state-of-the-art miniaturization and automation technologies to develop superior hand-held medical diagnostic and monitoring devices. By addressing the pain and inconvenience associated with current methods of blood glucose testing, Pelikan's product portfolio will eliminate the major obstacles to consistent glucose monitoring and vigorous diabetes management. The Pelikan Sun(TM) electronic lancing device strictly controls the entire lancing event, providing unparalleled comfort without calluses, bruising, or after-bleeding. In addition to Pelikan's initial focus on diabetes and blood glucose monitoring, the company's proprietary technology platform, supported by an extensive intellectual property portfolio, may be leveraged to develop state-of-the-art products for a variety of other medical conditions that involve blood screening and monitoring. Point-of-care testing and diagnostic panel test systems may eventually benefit from this novel technology.

For more information on Pelikan Technologies and the company's innovative products, please visit http://www.pelikantechnologies.com.


'/>"/>
SOURCE Pelikan Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PAs Best 50 Women in Business
4. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
5. Adnavance Technologies Inc. Appoints Christian P. Valcke, Ph.D., to Its Scientific Advisory Board
6. Sturgeon and Caviar From Aquaculture: United Food Technologies AG Hands Over Turnkey Plant
7. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
8. Veran Medical Technologies Secures $4.75M in First Institutional Funding
9. Neurobiological Technologies Reports Third Quarter Financial Results
10. InSet Technologies Appoints Jon Tremmel to its Board of Directors
11. Applied Isotope Technologies will Exclusively Supply Biochemimarker(TM) Discovery Products for a Unique Pilot Study on Autism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 2016 , ... KBioBox llc announced today the launch of ... a sophisticated “3 click” gene dditing off target analysis program and a “3 ... https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. Scientists, pharmaceutical researchers ...
(Date:12/8/2016)... , Dec. 8, 2016  Soligenix, Inc. ... biopharmaceutical company focused on developing and commercializing products ... unmet medical need, announced today the long-term follow-up ... SGX942 (dusquetide), a first-in-class Innate Defense Regulator (IDR), ... head and neck cancer patients undergoing chemoradiation therapy ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... has concluded that “in the setting of previously treated, advanced pancreatic cancer, liquid ... defining the optimal patient population and timing of blood sampling may improve the ...
Breaking Biology Technology:
(Date:11/28/2016)... 28, 2016 "The biometric ... 16.79%" The biometric system market is in the ... the near future. The biometric system market is expected ... at a CAGR of 16.79% between 2016 and 2022. ... biometric technology in smartphones, rising use of biometric technology ...
(Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... Medical LiveWire Healthcare and Life Sciences Awards as ... caps off an unprecedented year of recognition and growth ... for over 15 years. iMedNet ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
Breaking Biology News(10 mins):